News Hub | News Direct


Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

BioHarvest Sciences 1Q financials show continued growth with a 209% year-over-year increase

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share news the company has released first-quarter 2023 financial numbers that show big gains over 2022. The company saw VINIA revenues growing 209% compared to 1Q 2022, reaching $2.2 million. Sobel also shared with Proactive the company saw gross margins increase to 37%, from 26% a year earlier. The company is sticking with its guidance of year-over-year revenue growing three times to over $17 million. BioHarvest is looking to be cash flow break-even in 4Q 2023. Contact Details Proactive Investors Canada +1 604-688-8158

June 02, 2023 12:17 PM Eastern Daylight Time

Article thumbnail News Release

Willow Bioscience agrees to partnership with biotech company looking at age-related diseases

Willow Biosciences Inc.

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has agreed to a Master Services Agreement with an innovative biotech company with the focus on age-related diseases. This partnership will see the company develop precision fermentation processes for a class of molecules to develop novel solutions for age-related diseases. Savile also told Proactive about another key partnership with Kalsec Inc to develop an enzyme used in production of a new, advanced ingredient used in natural beverage applications. This is the second collaborative development program the two parties will be working on. The goal is to commercialize these products quickly and effectively, leveraging partnerships for market access while retaining the option to bring proprietary ingredients to market independently. Contact Details Proactive Investors +1 604-688-8158

June 02, 2023 11:51 AM Eastern Daylight Time

Article thumbnail Digital Asset Direct

MGC Pharmaceuticals to "keep chipping away" after first CannEpil delivery

MGC Pharmaceuticals Ltd

Contact Details Proactive UK Ltd +44 20 7989 0813

June 02, 2023 10:17 AM Eastern Daylight Time

Article thumbnail News Release

Revolutionize Preclinical Drug Candidate Discovery with Syntekabio

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) drug discovery and development company headquartered in South Korea, announced today the launch of its cost-effective AI-based total solution service for finding new drug candidates. STB CLOUD works as a comprehensive one-stop solution built on Syntekabio's own proprietary AI platform DeepMatcher®, powered by supercomputing technology. The total solution supports auto-hit-discovery, auto-lead-generation, auto-ADMET/PK (at task), and PGx biomarker for drug labeling. Using deep-learning analysis and automatic molecular dynamics (MD) simulation technology for target proteins, the solution generates pre-stage, pre-clinical candidates within two years, including the completion of animal testing. This process drastically shortens the period before pre-clinical trials to two years from what averages to be up to seven years in traditional drug development. Generally, it takes three to four years for candidate discovery and screening, one to three years for optimization, and the same length for non-clinical and toxicity tests. Adding five to six years for clinical trials and a couple more years for commercialization, the time it takes for full drug development from discovery can last many years causing the development price tag to go up while losing potential return on investment. Furthermore, Traditional new drug development can cost more than 10 million dollars until pre-clinical trials. Syntekabio’s STB CLOUD not only saves time but achieves substantial cost savings as it is set at only two million dollars for the entire cycle of drug development. “Using our AI-based STB CLOUD and supercomputing technology, we have created an optimal environment for servicing the global biopharma industry,” CEO of Syntekabio, Jongsun Jung, said. “The fully automated technology covers toxicity, metabolism and pharmacokinetics prediction and will provide in the near future an automated total service for each individual model. It’s only a matter of time to automatically produce drugs with high unmet needs, including rare disease treatments.” Currently, Syntekabio is conducting two studies in the area of auto-ADMET/PK (at task). The first is about toxicity and metabolism caused by protein binding, which is modeled based on the 3D convolutional neural network (3D-CNN). The second study is on passive delivery and permeability due to the physical and chemical properties of the compound itself, which will be implemented with pre-trained generative transformers models, such as GPT-2, using large-scale compound databases. Syntekabio’s new drug discovery solutions will be unveiled at the 2023 BIO International Convention in Boston, June 5-8 at booth #2785. Contact Ellie Woo at or +1 (917) 257-4533 to request one-on-one meeting. ### About Syntekabio Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at STB CLOUD ( Media Contact Syntekabio USA Email: Tel: +1 212-371-2544 Contact Details Syntekabio inc. Ellie Woo +1 212-371-2544 Company Website

June 01, 2023 05:00 PM Eastern Daylight Time

Article thumbnail News Release

Cohen Institute Mental Health Conference in Evanston to Focus on Managing Stress

The Chicago School of Professional Psychology

The Naomi Ruth Cohen Institute for Mental Health Education (NRCI) at The Chicago School of Professional Psychology (TCSPP) will bring together the community and professionals on June 10, 2023 to discuss "Untying the Human Knot: Managing Stress & Anxiety in Today's World." The conference is set for 9:30am-3:30pm at Evanston Township High School (1600 Dodge Ave., Evanston, Ill., 60201). Registration is available at the door. The 90-minute opening panel presentation features Gabriela Diaz, Orson Morrison, PhD, and Paula R. Young, PhD, ACT. The panel will be moderated by Michael Horowitz, PhD, President of The Community Solution Education System. The panel will be followed by three rounds of professional-led breakout sessions as well as a post-event networking session. Lunch is included. Gabriela Diaz is a Chicago-based actor, teaching artist, and mental health advocate. She received her BFA at Webster University’s Leigh Gerdine College of Fine Arts. She has worked with The Art Institute, Steppenwolf Theatre, Firebrand Theatre, Jackalope Theatre, and others. Gabriela has found a creative home at Erasing The Distance (ETD), where she combines her passion for the arts and mental health. As a person living with anxiety, Gabriela finds immense joy in sharing her story to spark dialogue about the human experience. Orson Morrison, PhD, is a licensed clinical psychologist and the co-owner of LifeSpan Counseling and Psychological Services. He is also the Associate Director of Clinical Services for DePaul University Counseling & Psychological Services. He has worked in a variety of clinical settings including college counseling centers, community mental health centers, medical settings, private practice, and in academic-clinical research units. His professional interests and areas of expertise include psychotherapy with children, adolescents, adults, and families; racial and intergenerational trauma; psychological assessment; and contemplative practices. Paula R. Young, PhD, ACT, is a licensed clinical psychologist and senior clinical director at Rogers Behavioral Health. There, she leads the clinicians who are focused on adolescent and adult mental health. Dr. Young, who received her doctorate from Finch University of Health Sciences/The Chicago Medical School, has extensive experience working with those with depression and anxiety disorders. She has presented to numerous clinical and academic audiences across the country. Michael Horowitz, PhD, is the President of The Community Solution Education System. Dr. Horowitz leads The Community Solution and its system of nonprofit colleges and universities including The Chicago School of Professional Psychology (TCSPP). Dr. Horowitz received his Ph.D. in Clinical Psychology from Northwestern University in 1986. The professional-led breakout sessions include informative presentations on topics like managing stress and anxiety at different stages of one’s life, building resilience, developing healthy coping mechanisms, and other topics. The conference is open to all community members and offers CEUs to licensed mental health and other professionals. Tickets will be available for $45 (with an added $25 for those seeking CEUs). Partial and full scholarships are available. Since 2002, NRCI has hosted an annual community mental health conference in Evanston, Ill., to bring together those with lived experience, their caregivers, supporters, and treatment professionals as well as members of the community interested in learning more about a specific mental health challenge or issue. NRCI is committed to providing mental health education and training in the Chicagoland area, and reducing the stigma often associated with mental health challenges and suicide, a cause the organization’s founders, Larry and Marilyn Cohen, embraced after their daughter Naomi died by suicide after living with bipolar disorder. About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit Contact Details Vivien Hao +1 323-893-4743

June 01, 2023 12:00 PM Eastern Daylight Time

Article thumbnail News Release

Galexxy Holdings Inc., Appoints High Profile Chief Marketing Officer


Galexxy Holdings Inc., (“Galexxy” or “Company”) (OTC: GXXY) is pleased to advise that it has appointed Dan Gay as its Chief Marketing and Sales Officer. Dan has a very successful background as a senior marketing and sales executive, adept at creating new markets, forming strategic sales alliances, and developing rapid growth of sales revenue. Dan’s early background includes senior positions with MCI Telecom (200 employees increased to 30,000 during his tenure), and Qwest, which grew to a $60 billion company. At MCI he managed sales teams in a 15-state region, which led national sales by adding $115m in new revenues. He became one of the highest-producing regions in the U.S. Dan also created and managed a 450-employee outreach Call Center, increasing MCI’s client base by 420,000 customers. At Qwest, Dan transformed an underperforming division to surpass plan and was chosen for the executive team that acquired and integrated the $44 billion US West telephone company. Dan was appointed Vice President and Chief Marketing Officer (CMO) of iThrive Health (2010-2017) a consortium targeting physicians and consumers with proprietary software offering 10,000-plus health products. Dan increased online revenues by 315%, grew the client base by 500%, and expanded SKUs six-fold. He also negotiated joint partnerships and led the successful acquisition of a related products company. More recently, in 2018 Dan was appointed Chief Marketing and Sales Officer of a leading blockchain growth company with employees and partner channels on 6 continents. As a member of the senior executive team, he tripled sales growth in 2022, brought 9 new products to market with thousands of daily downloads, and negotiated millions in angel investments. Galexxy’s CEO, Michael Biagi stated that; “Dan has the motivation and innovative expertise to build important strategic partnerships and drive our revenue growth to enable us to up-list onto NASDAQ”. Galexxy is headquartered in Newport Beach and its shares are publicly traded on the OTC Markets (OTC: GXXY). Galexxy entered the rapidly developing markets for premium natural plant-based health supplements and superfoods in April 2021, and completed its acquisition of Wellbeing Farms LLC., on August 4, 2022, and purchased 69% of ABC Wholesale Products LLC., on August 12, 2022. Galexxy Holdings Inc. CEO Michael Biagi E: M: (801) 243 9570 Forward-Looking Information This press release contains “forward-looking information” and “forward-looking statements” (collectively, “statements”). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this press release. Contact Details Galexxy Holdings Inc.

June 01, 2023 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Breaking News: WriteMyEssays And WriteMyPapers Merge. Learn More Here!

Halvorson Media Group

Recently, WriteMyEssays And WriteMyPapers signed a merger agreement. Find out what to expect from the changes, whether they will affect customers, and what new features are planned to be introduced. New York, May 28, 2021 — A few days ago, an academic writing company WriteMyEssays announced the acquisition of WriteMyPapers. This decision has been discussed for several months, and finally, there was official confirmation of the merger. Due to the inability to compete with other academic services, the WriteMyPapers brand decided to leave the market. In the past few months, the site has seen a surge in orders, and the staff has been unable to keep up with the influx. The departure of the company would have suffered great losses and the loss of valuable personnel. Thus, the decision to merge was the only correct one in this situation. The management bodies have already checked and approved the terms and conditions of the upcoming merger. What to Expect from The Merger? A merger is a complex business solution that takes time to set up internal processes. Of course, the company's management is going to consolidate high-quality academic writing in the industry and enter the international market. However, no one excludes the occurrence of difficulties, but first things first. At the moment, key stakeholders of both companies discussed several business benefits which can be expected in the near term. They are obvious, but are of great benefit to the company: Increasing the staff of the company. The staff of WriteMyPapers was more than 300 people. All writers pass under the control of the new owner. Thus, it means that the service will be able to process more orders and get more urgent assignments. Increasing the audience. Those customers who previously applied to WriteMyPapers are likely to start ordering essays and other assignments from a new company. Many students have been working with the same authors for several years, and they will be able to continue doing this under a new brand. Increasing monthly turnover. The more orders, the more income. This is a simple yet complex business rule. If the quality of the work performed remains at the same high level or becomes higher, the company will be able to increase income by 2-3 times. Moreover, this is a very significant indicator in the college writing industry. In the long term, the company expects the following positive changes: Entering the international market. In connection with scaling, it is planned to introduce new working languages. The managing department has ideas for covering European countries, China, and India. This will expand the audience by 5-6 times in the long run. Building a multi-level support system. Due to the increase in the audience, support representatives will need to be divided into several categories depending on the purpose: support for resolving payment issues, support for placing orders, support for submitting changes to orders, etc. Development of services in narrow areas. In a rapidly evolving environment, it is necessary to follow education trends. That is a real challenge to find specialists in AI engineering or bioinformatics with academic writing or teaching skills. However, this must be taken into account in order to be at the top of the best services. What Do The Experts Say? “The decision to merge was nothing short of a bold one for us. We expect to see results in two months. However, despite the encouraging results in the future, we understand that at first, the team may experience difficulties. Talks about a merger started early this year and we've more or less solidified the base to weather this challenging but promising time.” Harry Evans, WriteMyEssays Vice President “Our department will be the most heavily loaded, especially at the very start. We have developed an order distribution system that should help us not only cope with the number of incoming orders but also understand our strengths and weaknesses to improve the process. The scaling steps will be introduced smoothly, and we know we can adjust to new circumstances.” Emma Walker, Order Distribution Manager “We are pleased with the new changes and are ready to scale and introduce new services. Thanks to long-term planning and quick reaction to possible strategic changes, our company is moving into a higher orbit. We can call ourselves a company providing educational assistance services.” Caleb Ellington, Senior Manager About WriteMyEssays WriteMyEssays is an academic writing company that has been on the market for over 15 years. The company operates in the field of educational services, namely in writing papers of various formats for high school, college, and university students. The emphasis on "academic" demonstrates high standards of performance. At the moment, the company provides assistance in the following areas: academic writing, proofreading & editing, and problem-solving. These three services fully cover the needs of a broad student audience. The team assists with handling assignments of different levels: High School, Undergraduate, Bachelor, Master, and Professional. The company works in various fields: Mathematics, Literature, Chemistry, Architecture, Pharmacology, Law, and more than 30 other areas of study. The support service has every opportunity to select a performer with the appropriate education and academic writing skills. The list of services includes not only writing essays, but also making presentations, creating graphs and tables, writing speeches, typing, rewriting, performing mathematical calculations, helping with writing dissertations, conducting chemical, historical, mathematical, and literary analyzes, and much more. WriteMyEssays is often the choice of students due to the loyal pricing policy. Thanks to successful management and logistics, prices for services are kept below average. It allows students with a limited budget to place orders on the site. The company also often provides discounts and loyalty programs. With over 7,000 finished assignments, WriteMyEssays is one of the leaders in the professional student assistance industry. Most likely, new changes will lead this service to new achievements and the introduction of new services that meet the passage of time. On a Final Note The goal of the WriteMyEssays company is to remain competitive, gradually expanding the list of services, introducing new payment methods, and taking other equally important steps to be on top. The field of academic education is entering challenging times. It may not yet be obvious, but companies like WriteMyEssays will take on an inflated amount of workload to save education as a basic social sphere from a great collapse Contact Details Halvorson Media Group Edward +1 877-422-8205 Company Website

June 01, 2023 09:52 AM Eastern Daylight Time

Article thumbnail News Release

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

OKYO Pharma

By David Willey, Benzinga The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio (NASDAQ: ISEE). Iveric Bio’s focus is on developing innovative treatments for eye diseases. Through the purchase, Astellas has signaled it will be sharpening its focus in the field of ‘blindness and regeneration’. The price for the acquisition was set at $5.9 billion, and following the news Iveric’s stock (ISEE) rose 17.9% to $38.79. The global ophthalmology market was worth $33.56 billion in 2022 and is predicted to reach $54.87 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.4% during the forecast period. A trend in the market is toward finding novel treatments and innovative drug delivery systems, and this trend is driving research in the sector. A second recent major acquisition in the sector was Viatris, Inc. ’s (NASDAQ: VTRS) acquisition of Oyster Point Pharma and Famy Life Sciences at the beginning of the year. The acquisition, for a combined $695 million, allowed the global healthcare company to establish Viatris Eye Care Division. Dry Eye Disease And OKYO A range of ocular diseases, like glaucoma, uveitis and retinal diseases are most prevalent in the geriatric population, and rates of disease are increasing as the population ages. One of the most common ocular diseases is dry eye disease (DED). It affects almost 50 million people in the US, and the global market for DED was worth $4.5 billion in 2022. It is predicted to reach $6.3 billion by 2028, at a compound annual growth rate (CAGR) of 5.67% during the forecast period. OKYO Pharma Ltd. (NASDAQ: OKYO) is a biopharma leading the way when it comes to developing novel treatments for DED and ocular pain. Founded in 2018, the company was able to bypass phase 1 safety trials and has begun screening patients for its phase 2 efficacy trials. The trial includes 240 patients, and OKYO anticipates having topline data on its drug, OK-101, in Quarter 4 of 2023. OK-101 uses a novel chemerin receptor that both acts as an anti-inflammatory agent and reduces corneal neuropathic pain in the patient. As the treatment is administered topically as eye drops, there is almost no risk of systemic exposure or risk of the treatment getting into the bloodstream. If the trial meets its pre-specified endpoints, this could contribute data toward registration trials, and speed up OK-101’s timeline for approval from the Food and Drug Administration (FDA). The company is laser-focused on bringing its treatment to market, as it believes the treatment has significant potential in the sector. With recent acquisitions indicating a commitment from big biopharmaceuticals to the ophthalmology market, there may be many eyes watching the progress of OKYO’s phase 2 trials. Keep up with OKYO’s developments in the eye care market on its website. OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR Company Website

June 01, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Leidos Becomes First Major Prime Contractor to Adopt NCMA Contract Management Standard

National Contract Management Association

Leidos (NYSE: LDOS), a FORTUNE® 500 science and technology leader, today announced its intent to adopt the National Contract Management Association’s (NCMA) Contract Management Standard ™ (CMS™). By adopting this standard, Leidos will align its workforce competency with the standard recently adopted by the federal government and institutions of higher education. With this adoption, Leidos builds on its long-standing commitment to strong customer relationships through standards of professional conduct and common understanding. The company is committed to developing the contract management profession as a meaningful and rewarding career path. This will support practitioners across industry and government who serve the federal mission. “Leidos Contracting is excited to lead the industry in the adoption of the CMS™,” said Kim Denver, Leidos Senior Vice President and Chief Corporate Contracts Executive. “Contract management professionals are paramount to mission success. Through the CMS framework, our tradecraft will be incorporated under one common standard, elevating both federal and industry contract management professionals who are critical to our nation’s success.” “NCMA is pleased to have Leidos join the growing community of CMS™ adopters dedicated to building a stronger bridge between industry and government,” said NCMA Chief Executive Officer Kraig Conrad. “This adoption reinforces Leidos' commitment to the profession; their contract management teams and the missions we serve together.” The U.S. Office of Federal Procurement Policy (OFPP) announced the new classification in a January 19 memo, stating that the CMS™ will become the foundation of a new contracting training system for all civilian agencies effective February 1, 2023. The new Federal Acquisition Certification in Contracting (FAC-C) (Professional) will now align with the Department of Defense framework (DAWIA), which is also based on the CMS™. The American National Standards Institute (ANSI)-approved third edition of the NCMA CMS™ is recognized globally as the preeminent standard in the profession. It serves as the basis for hiring and training frameworks as well as the NCMA’s ANSI National Accreditation Board (ANAB)-accredited Certified Contract Management Associate (CCMA) certification. The National Contract Management Association (NCMA), which was founded in 1959 and is the world’s leading association in the field of contract management. The organization, which has over 18,000 members, is dedicated to the professional growth and educational advancement of procurement and acquisition personnel worldwide. NCMA strives to serve and inform the profession and industry it represents and to offer opportunities for the open exchange of ideas in neutral forums. To find out more, please visit About Leidos Leidos is a Fortune 500® technology, engineering, and science solutions and services leader working to solve the world’s toughest challenges in the defense, intelligence, civil, and health markets. The company’s 45,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $14.4 billion for the fiscal year ended December 30, 2022. For more information, visit ### Certain statements in this announcement constitute “forward-looking statements” within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the “Risk Factors” set forth in Leidos’ Annual Report on Form 10-K for the fiscal year ended December 30, 2022, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made. Contact Details NCMA Holly DeHesa +1 281-865-3296 Company Website

June 01, 2023 07:55 AM Eastern Daylight Time

12345 ... 189